Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

Executive Summary

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.

Advertisement

Related Content

AZ Inks Machine Learning Deal With BenevolentAI
Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe
Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes
Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules
Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies
Ipsen Commercial Chief: Buying Clementia Will Bolster Rare Disease Franchise
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125141

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel